Vanda Pharmaceuticals (VNDA) said Monday that the US Food and Drug Administration has accepted the new drug application for Bysanti to potentially treat bipolar I disorder and schizophrenia, with a target decision date of Feb. 21, 2026.
The FDA has not identified any potential review issues at this time, Vanda said.
The company said the application is supported by data from studies in acute episodes of schizophrenia, a study in bipolar I disorder with manic or mixed episodes, and a relapse prevention study in schizophrenia.
Bysanti is currently being evaluated as a once-daily add-on treatment for major depressive disorder, with results expected in 2026, the biopharmaceutical company said.
Shares of Vanda Pharmaceuticals were down more than 2% in recent Monday trading.
Price: 4.47, Change: -0.10, Percent Change: -2.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。